Suppr超能文献

人肿瘤中的胆囊收缩素(CCK)-A 及 CCK-B/胃泌素受体

Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.

作者信息

Reubi J C, Schaer J C, Waser B

机构信息

Division of Cell Biology and Experimental Cancer Research, University of Berne, Switzerland.

出版信息

Cancer Res. 1997 Apr 1;57(7):1377-86.

PMID:9102227
Abstract

Cholecystokinin (CCK)-A and CCK-B/gastrin receptors were evaluated with in vitro receptor autoradiography in 406 human tumors of various origins using a sulfated 125I-labeled CCK decapeptide analogue 125I-(D-Tyr-Gly, Nle28,3l)-CCK 26-33 and 125I-labeled Leu15-gastrin as radioligands. CCK-B/gastrin receptors were found frequently in medullary thyroid carcinomas (92%), in small cell lung cancers (57%), in astrocytomas (65%), and in stromal ovarian cancers (100%). They were found occasionally in gastroenteropancreatic tumors, breast, endometrial, and ovarian adenocarcinomas. They were either not expressed or rarely expressed in colorectal cancers, differentiated thyroid cancers, non-small cell lung cancers, meningiomas, neuroblastomas, schwannomas, glioblastomas, lymphomas, renal cell cancers, prostate carcinomas, and the remaining neuroendocrine tumors (i.e., pituitary adenomas, pheochromocytomas, paragangliomas, and parathyroid adenomas). CCK-A receptors were expressed rarely in tumors except in gastroenteropancreatic tumors (38%), meningiomas (30%), and some neuroblastomas (19%). The identified CCK-A and CCK-B receptors were specific and of high affinity in the subnanomolar range. The rank order of potency of various CCK analogues was: sulfated CCK-8 = L-364,718 >> nonsulfated CCK-8 = L-365,260 > or = gastrin for CCK-A receptors and sulfated CCK-8 > gastrin = nonsulfated CCK-8 > L-365,260 > L-364,718 for CCK-B receptors. CCK-B receptors could also be selectively and specifically labeled with a newly designed nonsulfated 125I-(D-Tyr-Gly, Nle28,31)-CCK 26-33. Gastrin mRNA measured by in situ hybridization was present in most CCK-B receptor-positive small cell lung cancers, breast tumors, and ovarian tumors, representing the molecular basis of a possible autocrine growth regulation of these tumors. Gastrin and CCK mRNAs were lacking in medullary thyroid cancers. Thus, these results may have pathogenic, diagnostic, differential diagnostic, and therapeutic implications.

摘要

采用硫酸化的¹²⁵I标记的胆囊收缩素(CCK)十肽类似物¹²⁵I-(D-酪氨酸-甘氨酸,Nle²⁸,³¹)-CCK ²⁶⁻³³和¹²⁵I标记的亮氨酸¹⁵⁻胃泌素作为放射性配体,通过体外受体放射自显影技术对406例不同来源的人类肿瘤中的CCK-A和CCK-B/胃泌素受体进行了评估。CCK-B/胃泌素受体常见于甲状腺髓样癌(92%)、小细胞肺癌(57%)、星形细胞瘤(65%)和卵巢基质癌(100%)。在胃肠胰肿瘤、乳腺癌、子宫内膜癌和卵巢腺癌中偶尔发现。在结直肠癌、分化型甲状腺癌、非小细胞肺癌、脑膜瘤、神经母细胞瘤、神经鞘瘤、胶质母细胞瘤、淋巴瘤、肾细胞癌、前列腺癌以及其余神经内分泌肿瘤(即垂体腺瘤、嗜铬细胞瘤、副神经节瘤和甲状旁腺瘤)中,它们要么不表达,要么很少表达。CCK-A受体除了在胃肠胰肿瘤(38%)、脑膜瘤(30%)和一些神经母细胞瘤(19%)中外,在肿瘤中很少表达。所鉴定的CCK-A和CCK-B受体具有特异性且在亚纳摩尔范围内具有高亲和力。各种CCK类似物的效价顺序为:硫酸化CCK-8 = L-364,718 >> 非硫酸化CCK-8 = L-365,260 ≥ 胃泌素(对于CCK-A受体),以及硫酸化CCK-8 > 胃泌素 = 非硫酸化CCK-8 > L-365,260 > L-364,718(对于CCK-B受体)。CCK-B受体也可以用新设计的非硫酸化¹²⁵I-(D-酪氨酸-甘氨酸,Nle²⁸,³¹)-CCK ²⁶⁻³³进行选择性和特异性标记。通过原位杂交测量的胃泌素mRNA存在于大多数CCK-B受体阳性的小细胞肺癌、乳腺肿瘤和卵巢肿瘤中,这代表了这些肿瘤可能的自分泌生长调节的分子基础。甲状腺髓样癌中缺乏胃泌素和CCK mRNA。因此,这些结果可能具有致病、诊断、鉴别诊断和治疗意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验